MAYO CLINIC
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1889-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.mayoclinic.org
Common Genetic Variation and Type 2 Diabetes
Completed
- Conditions
- Pre-diabetes
- Interventions
- Other: Oral glucose tolerance test
- First Posted Date
- 2008-07-01
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 190
- Registration Number
- NCT00707616
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Improved Time in Therapeutic Range With Patient Self-Testing of Their INR Compared to Usual Care
Not Applicable
Completed
- Conditions
- Management of Anticoagulation
- Interventions
- Other: Usual CareDevice: INRatio monitor by Hemosense
- First Posted Date
- 2008-06-24
- Last Posted Date
- 2014-08-28
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 200
- Registration Number
- NCT00703963
- Locations
- 🇺🇸
Saint Marys Hospital, Rochester, Minnesota, United States
Contact Allergies to Dental Metal as a Possible Risk Factor for Oral Cancer
Completed
- Conditions
- Head and Neck Cancer
- First Posted Date
- 2008-06-09
- Last Posted Date
- 2011-06-08
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 115
- Registration Number
- NCT00693550
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase 1
Terminated
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- First Posted Date
- 2008-06-02
- Last Posted Date
- 2019-08-20
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 13
- Registration Number
- NCT00687674
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Prolotherapy Versus Steroids for Thumb Carpo-metacarpal Joint Arthritis
Not Applicable
Terminated
- Conditions
- Thumb Carpometacarpal Joint Osteoarthritis
- Interventions
- Drug: Prolotherapy (10% dextrose solution)Drug: Betamethasone
- First Posted Date
- 2008-05-29
- Last Posted Date
- 2012-08-30
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 2
- Registration Number
- NCT00685880
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Leuprolide, Bicalutamide, and Implant Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer After External-Beam Radiation Therapy
Phase 2
Completed
- Conditions
- Prostate Cancer
- First Posted Date
- 2008-05-28
- Last Posted Date
- 2012-11-12
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 50
- Registration Number
- NCT00684905
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Comparison of Cyanoacrylate Tissue Adhesive and Suture for Closure of Cardiac Device Pockets
Not Applicable
Terminated
- Conditions
- Cardiovascular Disease
- Interventions
- Device: Cyanoacrylate tissue adhesive (Dermabond)Device: Polyglactin 910 suture (Vicryl)
- First Posted Date
- 2008-05-07
- Last Posted Date
- 2010-12-29
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 103
- Registration Number
- NCT00674128
- Locations
- 🇺🇸
Mayo Clinic, Phoenix, Arizona, United States
Endothelial Function and Autonomic Regulation After Short-term Smoking Cessation: Varenicline Versus Placebo
- First Posted Date
- 2008-05-07
- Last Posted Date
- 2012-03-16
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 19
- Registration Number
- NCT00673595
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma
Phase 1
Active, not recruiting
- Conditions
- Lymphoma
- First Posted Date
- 2008-05-01
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 138
- Registration Number
- NCT00670358
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
CC-4047 in Treating Patients With Myelofibrosis
Phase 1
Completed
- Conditions
- Secondary MyelofibrosisChronic Myeloproliferative Disorders
- Interventions
- Drug: CC-4047
- First Posted Date
- 2008-04-30
- Last Posted Date
- 2019-12-30
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 77
- Registration Number
- NCT00669578
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
© Copyright 2025. All Rights Reserved by MedPath